Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.74 |
| ▸ | PTGES | O14684 | 1/20 | 0.70 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | RGS12 | O14924 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13802422 | 0.91 | PTGDR2 (0.76) | PTGDR2PTGESALOX5LMNACYP1A2 | |
| SCHEMBL4270126 | 0.89 | THRA (0.71) | PTGDR2PTGESALOX5LMNACYP1A2 | |
| SCHEMBL4211522 | 0.88 | PTGDR2 (0.72) | PTGDR2PTGESALOX5LMNACYP1A2 | |
| SCHEMBL13802405 | 0.86 | PTGDR2 (0.70) | PTGDR2PTGESALOX5THRATHRB | |
| SCHEMBL4200412 | 0.85 | PTGDR2 (0.69) | PTGDR2PTGESALOX5LMNACYP1A2 | |
| SCHEMBL13802404 | 0.85 | PTGDR2 (1.00) | PTGDR2PTGESALOX5THRATHRB | |
| SCHEMBL7698765 | 0.84 | ALDH1A1 (0.57) | PTGDR2PTGESALOX5LMNACYP1A2 | |
| SCHEMBL6025562 | 0.84 | MAPT (0.73) | PTGDR2PTGESALOX5LMNACYP1A2 | |
| SCHEMBL20769712 | 0.83 | PTGDR2 (0.69) | PTGDR2PTGESALOX5MEN1ALDH1A1 | |
| SCHEMBL13802427 | 0.82 | THRA (0.65) | PTGDR2PTGESALOX5THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2002020478-A1 | N-BENZYLINDOLE-3-ACETIC ACID DERIVATIVES FOR USE IN THE TREATMENT OF DRUG RESISTAN CANCER | DUBLIN CITY UNIVERSITY (IE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | PTGDR2 2287/4885PTGES 1518/4885ALOX5 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.